QCLS insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. 10% owner · Q/C TECHNOLOGIES, INC. | QCLS Q/C TECHNOLOGIES, INC. | Other transactionFiling detailsSEC transaction code J Series H Convertible Preferred Stock · Derivative security · Direct ownership · Reported balance after transaction: 3000 · Each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of Common Stock, based on the current conversion price of $0.3101 per share, subject to adjustment. · On November 18, 2026, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027, for no additional consideration. Any deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d), and the cancellation also is exempt from reporting under Rule 16a-4(d) | 2026-11-18 | 2026-11-20 | 3,000 shares/units | SEC 4 | Follow |
| PharmaCyte Biotech, Inc. 10% owner · Q/C TECHNOLOGIES, INC. | QCLS Q/C TECHNOLOGIES, INC. | Exercise or conversionFiling detailsSEC transaction code X Series G Long-Term Warrants · Derivative security · Direct ownership · Reported balance after transaction: 13318344 · Series G Long-Term Warrants are exercisable for shares of Common Stock at an exercise price of $0.3101 per share, subject to adjustment. · On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement. | 2026-11-18 | 2026-11-20 | 851,304 shares/units | SEC 4 | Follow |
| PharmaCyte Biotech, Inc. 10% owner · Q/C TECHNOLOGIES, INC. | QCLS Q/C TECHNOLOGIES, INC. | Exercise or conversionFiling detailsSEC transaction code X Common stock · Direct ownership · Reported balance after transaction: 5152000 · On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement. · Includes 169,728 shares of Common Stock acquired as payment of Series G Dividends exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-9(a) promulgated thereunder. | 2026-11-18 | 2026-11-20 | 4,982,272 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.